此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

改善安全网设置中的高血压控制:波士顿高血压股权联盟治疗 (BHEAT)

2026年9月27日 更新者:Boston Medical Center

干预措施改善安全网络中高血压控制的比较有效性:治疗中的波士顿高血压联盟

High blood pressure (BP) or hypertension (HTN) affects over 100 million individuals in the US, increasing the risk of adverse outcomes, including stroke, myocardial infarction (MI), and chronic kidney disease (CKD). Effective therapies include non-pharmacologic approaches and multiple medication classes. Successful HTN management requires ongoing patient engagement for BP monitoring and treatment intensification. Reaching this goal is challenging, and many patients with HTN do not have controlled BP.

Using a collaborative partnership between patients, clinicians, health system and public health stakeholders, and the research team the investigators plan to overcome barriers to widespread implementation of evidence-based health system strategies to improve BP control in a large, urban, primary care-based safety-net setting for diverse populations experiencing disparities in HTN-related outcomes.

研究概览

详细说明

A hybrid type 1 effectiveness-implementation study will be implemented to evaluate the comparative impact of each intervention on clinical outcomes while also assessing implementation at each site. The multi-site cluster randomized stepped-wedge design allows for feasible resource allocation and sequential roll out of the interventions for comparison, ensuring each site has the opportunity to benefit from both approaches. Data will be collected for multiple patient reported outcomes (PROs) to understand the range of impacts of the interventions from the patient perspective.

The specific aims are to:

  • Assess comparative effectiveness of remote BP monitoring (RBPM) versus RBPM + multilevel intensification intervention (MII) on HTN control and quality of care. Prior research has demonstrated the effectiveness of each of these interventions yet the optimal approach to achieve equity in HTN control in safety net practices remains unknown.
  • Use mixed methods, guided by the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework, to assess implementation of the two comparators as measured by reach, adoption, implementation (fidelity) and maintenance. Using a convergent parallel design, the investigators will use concurrent quantitative and qualitative data to obtain perspectives across multiple levels to understand the reasons for success or failure of implementation of each comparator. By merging these data, integration can be achieved by using qualitative themes related to implementation to support or refute quantitative findings of reach and fidelity.
  • Evaluate the comparative impacts of each intervention on PROs assessed with validated measures of patient activation, medication adherence, and trust in medical settings. The study intervention approaches were informed by direct feedback from the targeted diverse patients and clinical providers to address patient-reported barriers to HTN control: lack of activation, adherence to medications, and trust in their care providers.

研究类型

介入性

注册 (估计的)

16895

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Massachusetts
      • Boston、Massachusetts、美国、02118
        • 招聘中
        • Boston Healthcare for the Homeless (BHCHP)
      • Boston、Massachusetts、美国、02118
        • 招聘中
        • Boston Medical Center Family Medicine
      • Boston、Massachusetts、美国、02118
        • 招聘中
        • Boston Medical Center, General Internal Medicine primary care
      • Boston、Massachusetts、美国、02118
        • 招聘中
        • Neighborhood Health
      • Boston、Massachusetts、美国、02126
        • 招聘中
        • Mattapan Community Health Center
      • Quincy、Massachusetts、美国、02169
        • 招聘中
        • Manet Community Health Center
      • Roslindale、Massachusetts、美国、02131
        • 招聘中
        • Greater Roslindale Medical and Dental Center (GRMDC)

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Adult (age>18) patients receiving primary care at one of the 9 participating sites, with primary care provider (PCP) visit in the preceding year
  • Presence of HTN defined by one or more of: 1) diagnosis included on active problem list, 2) active HTN medications in prior year, 3) 3 separate elevated BP measurements
  • Uncontrolled HTN defined as systolic blood pressure (SBP)>140

Exclusion Criteria:

  • Not meeting the inclusion criteria

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:卫生服务研究
  • 分配:随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Remote Blood Pressure Monitoring (RBPM)

Individual level interventions fo monitor blood pressure.

Standardized blood pressure measurement and treatment protocols in clinical practice.

实验性的:Multilevel Intensification interventions (MII)

Team-based interventions to mitigate clinical inertia which is the lack of intensification of treatment despite inadequate disease control such as for HTN.

Standardized blood pressure measurement and treatment protocols in clinical practice.

Team-based interventions including multiple evidence-proven interventions such as clinician decision support, monitoring medication non-adherence, use of combination pills, and formulary modifications.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Systolic blood pressure (SBP) improvement
大体时间:Baseline, every 3 months up to 54 months

Change in BP abstracted from the electronic health record (EHR).

Baseline, every 3 months up to 54 months
Interventions received
大体时间:Baseline, 54 months

The number and proportion of individuals who receive each intervention.

Baseline, 54 months
Patient activation
大体时间:Baseline, 18 months, 30 months, 36 months, 42 months, 54 months

Patient activation will be assessed with the Consumer Health Activation index (CHAI), a 10 item validated instrument that generates a score of 0-100, with ≥80 indicating moderate/high activation.

Baseline, 18 months, 30 months, 36 months, 42 months, 54 months

次要结果测量

结果测量
措施说明
大体时间
Blood pressure control
大体时间:Baseline, 18 months, 30 months, 36 months, 42 months, 54 months

Assessed as Yes/No from EHR records for Systolic BP<140 mmHg and Systolic BP<130 mmHg.

Baseline, 18 months, 30 months, 36 months, 42 months, 54 months
Medication intensification
大体时间:Baseline, 18 months, 30 months, 36 months, 42 months, 54 months

Assessed from EHR and claims data.

Baseline, 18 months, 30 months, 36 months, 42 months, 54 months
BP monitoring
大体时间:Baseline, 18 months, 30 months, 36 months, 42 months, 54 months

Assessed by EHR data on the frequency of BP monitoring.

Baseline, 18 months, 30 months, 36 months, 42 months, 54 months
Fidelity of interventions
大体时间:Baseline, 18 months, 30 months, 36 months, 42 months, 54 months

The number and proportion of individuals who receive all key elements of the interventions based on EHR data.

Baseline, 18 months, 30 months, 36 months, 42 months, 54 months
Medication adherence
大体时间:Baseline, 18 months, 30 months, 36 months, 42 months, 54 months

the 3-item self-report scale by Wilson will be used to assess this outcome. It queries patients about how many days they missed medications and overall consistency over the last 30 days. This measure has been standardized to a 0-100 scale, with good adherence defined as ≥80.

Baseline, 18 months, 30 months, 36 months, 42 months, 54 months
Trust in primary care
大体时间:Baseline, 18 months, 30 months, 36 months, 42 months, 54 months

Assessed with the 10 item Wake Forest Physician Trust Scale. The scale uses a 5-point Likert scale [1=strongly disagree to 5=strongly agree]. Total scores can range from 10 to 50, and higher scores represent greater trust.

Baseline, 18 months, 30 months, 36 months, 42 months, 54 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年9月8日

初级完成 (估计的)

2029年9月1日

研究完成 (估计的)

2029年9月1日

研究注册日期

首次提交

2025年4月15日

首先提交符合 QC 标准的

2025年4月21日

首次发布 (实际的)

2025年4月29日

研究记录更新

最后更新发布 (实际的)

2026年9月30日

上次提交的符合 QC 标准的更新

2026年9月27日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • H-45398
  • HMC-2023C2-33345 (其他赠款/资助编号:Patient-Centered Outcomes Research Institute (PCORI))

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅